北京昭衍新药研究中心股份有限公司关于员工持股计划回购股份注销实施公告

Core Viewpoint - The company, Beijing Zhaoyan New Drug Research Center Co., Ltd., has decided to terminate its employee stock ownership plans for 2021 and 2022, leading to the repurchase and cancellation of a total of 129,114 shares [1][5]. Group 1: Employee Stock Ownership Plans - The 2021 A-share employee stock ownership plan was approved by the board and shareholders but was never established due to lack of participation [2]. - The 2022 A-share employee stock ownership plan was also approved, but the company later decided to terminate it [3][5]. Group 2: Share Repurchase and Cancellation - The company will cancel a total of 129,114 shares from the repurchase account due to the termination of the employee stock ownership plans [9]. - The cancellation of shares will change the total share capital from 749,477,334 shares to 749,348,220 shares [11]. Group 3: Decision Process and Compliance - The decision to terminate the employee stock ownership plans and cancel shares was made after careful consideration of the macroeconomic environment and was agreed upon by the participating employees [8]. - The company has ensured that the decision-making process and information disclosure comply with relevant laws and regulations [12].